Mardepodect

Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier[1][2].

Product Specifications

CAS Number

[898562-94-2]

Product Name Alternative

PF-2545920

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/PF-2545920.html

Purity

98.81

Solubility

DMSO : ≥ 45 mg/mL

Smiles

CN(N=C1C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C=C1C5=CC=NC=C5

Molecular Formula

C25H20N4O

Molecular Weight

392.45

Precautions

H302, H315, H319

References & Citations

[1]Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4- (1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl) -phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem, 2009, 52 (16), 5188-5196.|[2]Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331 (2), 574-590.